To further prove the versatility of the CEM method, we applied CEM to three additional cell lines (human cervical cancer HeLa cells, human embryonic kidney HEK293 cells and adenocarcinomic human alveolar basal epithelial A549 cells), to determine if suppression of Survivin mRNA is achieved with a known clinical phase Survivin-targeting ASO (Survivin-BNA (16), Supplementary Table S1) (21). This evidence concerns the gene BIRC5 and cervical cancer.